Univariate and multivariate analyses for CIR, NRM, RFS, and OS in AML patients (n = 96)
| End point . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% CI . | P . | HR* . | 95% CI . | P . | |
| CIR | ||||||
| MRD+ vs MRD− | 5.58 | 2.47-12.59 | <.001 | 5.67 | 2.30-14.0 | <.001 |
| DNMT3A mutant vs wild type | 0.41 | 0.17-0.97 | .042 | 0.33 | 0.12-0.89 | .029 |
| FLT3-ITD present vs absent | 0.91 | 0.38-2.15 | .828 | 3.70 | 1.36-10.10 | .011 |
| NPM1 mutant vs wild type | 0.19 | 0.04-0.81 | .025 | 0.22 | 0.06-0.77 | .018 |
| NRM | ||||||
| AML type secondary vs de novo AML | 6.25 | 1.58-24.63 | .009 | 5.64 | 1.80-17.65 | .003 |
| Age >60 vs 18-60 y | 3.93 | 1.07-14.43 | .039 | 7.13 | 1.75-29.16 | .006 |
| KRAS mutant vs wild type | 5.44 | 1.6-18.46 | .007 | 19.4 | 3.32-113 | .001 |
| NPM1 mutant vs wild type | 1.92 | 0.48-7.73 | .356 | 4.42 | 1.70-11.52 | .002 |
| RFS | ||||||
| MRD+ vs MRD− | 3.56 | 1.86-6.81 | <.001 | 3.41 | 1.72-6.75 | .001 |
| Age >60 vs 18-60 y | 1.89 | 1.02-3.49 | .043 | 2.23 | 1.15-4.33 | .017 |
| KRAS mutant vs wild type | 2.13 | 1.03-4.39 | .041 | 3.51 | 1.64-7.50 | .001 |
| TP53 mutant vs wild type | 2.74 | 1.30-5.79 | .008 | 2.26 | 1.09-4.70 | .029 |
| OS | ||||||
| MRD+ vs MRD− | 3.06 | 1.54-6.12 | .002 | 3.00 | 1.41-6.38 | .004 |
| Conditioning MAC vs RIC | 0.54 | 0.28-1.02 | .056 | 0.37 | 0.20-0.69 | .002 |
| KRAS mutant vs wild type | 2.84 | 1.33-6.05 | .007 | 5.58 | 2.68-11.62 | <.001 |
| TP53 mutant vs wild type | 3.57 | 1.67-7.61 | .001 | 3.97 | 1.90-8.29 | <.001 |
| End point . | Univariate analysis . | Multivariate analysis . | ||||
|---|---|---|---|---|---|---|
| HR* . | 95% CI . | P . | HR* . | 95% CI . | P . | |
| CIR | ||||||
| MRD+ vs MRD− | 5.58 | 2.47-12.59 | <.001 | 5.67 | 2.30-14.0 | <.001 |
| DNMT3A mutant vs wild type | 0.41 | 0.17-0.97 | .042 | 0.33 | 0.12-0.89 | .029 |
| FLT3-ITD present vs absent | 0.91 | 0.38-2.15 | .828 | 3.70 | 1.36-10.10 | .011 |
| NPM1 mutant vs wild type | 0.19 | 0.04-0.81 | .025 | 0.22 | 0.06-0.77 | .018 |
| NRM | ||||||
| AML type secondary vs de novo AML | 6.25 | 1.58-24.63 | .009 | 5.64 | 1.80-17.65 | .003 |
| Age >60 vs 18-60 y | 3.93 | 1.07-14.43 | .039 | 7.13 | 1.75-29.16 | .006 |
| KRAS mutant vs wild type | 5.44 | 1.6-18.46 | .007 | 19.4 | 3.32-113 | .001 |
| NPM1 mutant vs wild type | 1.92 | 0.48-7.73 | .356 | 4.42 | 1.70-11.52 | .002 |
| RFS | ||||||
| MRD+ vs MRD− | 3.56 | 1.86-6.81 | <.001 | 3.41 | 1.72-6.75 | .001 |
| Age >60 vs 18-60 y | 1.89 | 1.02-3.49 | .043 | 2.23 | 1.15-4.33 | .017 |
| KRAS mutant vs wild type | 2.13 | 1.03-4.39 | .041 | 3.51 | 1.64-7.50 | .001 |
| TP53 mutant vs wild type | 2.74 | 1.30-5.79 | .008 | 2.26 | 1.09-4.70 | .029 |
| OS | ||||||
| MRD+ vs MRD− | 3.06 | 1.54-6.12 | .002 | 3.00 | 1.41-6.38 | .004 |
| Conditioning MAC vs RIC | 0.54 | 0.28-1.02 | .056 | 0.37 | 0.20-0.69 | .002 |
| KRAS mutant vs wild type | 2.84 | 1.33-6.05 | .007 | 5.58 | 2.68-11.62 | <.001 |
| TP53 mutant vs wild type | 3.57 | 1.67-7.61 | .001 | 3.97 | 1.90-8.29 | <.001 |
MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.
HRs >1 or <1 indicate an increased or decreased risk, respectively.